We are leading the way in developing green, enabling biotechnology and nanotechnology drug delivery platforms, and enhanced therapeutic products for health maintenance, disease prevention and the treatment of certain cancers, infectious diseases and CNS disorders such as Alzheimer’s Disease.
Using advanced scientific techniques, we are improving drug delivery, accelerating the drug discovery and manufacturing process, removing harmful pathogens from biologics and the human blood supply and working to provide a viable biofuel solution for the future.
We are developing enhanced therapeutics for treating cancers and their side-effects, infectious diseases such as HIV and Influenza, and CNS disorders. We also manufacture quality-of-life medicines for health maintenance, research chemicals for standards, APIs for pharmaceuticals and equipment for our enabling technology platforms.
We are seeking partners and investors to further the development and utilization of our enabling technology platforms and enhanced therapeutic products. We are interested in working with individuals and companies dedicated to improving quality of life, maintaining health and treating unmet medical needs.
President & CEO Dr. Trevor P. Castor talks about the company and its prostate cancer program. Watch video >
Aphios has published its article "Acute Oral Bryostatin-1 Administration Improves Learning Deficits in the APP/PS1 Transgenic Mouse Model of Alzheimer's Disease" in the publication Current Alzheimer Research. More >